Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

John Carroll

Editor & Founder

Close to 3 years after Vertex helped Arbor Biotechnologies get off the ground with a reputation-building alliance to build gene-editing tools for a suite of core diseases, including cystic fibrosis, they’ve come back to go up to $1.2 billion deeper into their shared journey of discovery. Only this time they’re collaborating on ex vivo engineered cell therapies.

They’ve broadened the sphere of their work with the biotech, going after type 1 diabetes as well as sickle cell disease and beta thalassemia — plus a few that are being left off the radar for now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ther­a­pies

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir